Mental bulimia , paroxetine treatment and phenotype monitoring
of CYP2D6 activity

D 2007

Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity

PALČÍKOVÁ, Ivana, Alexandra ŽOURKOVÁ, Daria VALENTOVÁ and Eva HADAŠOVÁ

Basic information

Original name

Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity

Name in Czech

Sledování fenotypových změn CYP2D6 při léčbě bulimie paroxetinem

Authors

PALČÍKOVÁ, Ivana, Alexandra ŽOURKOVÁ, Daria VALENTOVÁ and Eva HADAŠOVÁ

Edition

Brno, Addiction and Eating Disorders, Neurobiology nad Comorbidities, Workshop, p. 59-60, 2 pp. 2007

Publisher

Masaryk University Conference Centre, Czech Republic, Brno

Other information

Language

English

Type of outcome

Stať ve sborníku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Medicine

ISBN

978-80-87041-18-5

Keywords in English

bulimia; CYP2D6; paroxetine

Abstract

ORIG CZ

V originále

P450 enzymes are oxidase systems. These enzymes oxidize endogenous and exogenous compounds and usually render them less active, preparing them for elimination from the body. More than 40 individual P450 enzymes have been identified. 2D6 play important role in drug metabolism. SSRI (serotonin reuptake inhibitors) therapy is used in bulimia. There are SSRI, especially paroxetine, with a SSRI-inhibiting effect. This fact may lead to a change of phenotype. Phenotyping enables to identify the current activity of the enzyme. The study included patients diagnosed with bulimia. The goal of the study was to evaluate the efficacy of paroxetine treatment in female patients with mental bulimia (MB) while monitoring CYP2D6 activity. Treatment was evaluated on EAT, HAMA, CGI and UKU scales. CYP2D6 activity phenotyping was performed using the dextromethorphan test. The expectation of a significant improvement in poor metabolizers and consequently slower paroxetine degradation was confirmed on the scale for eating behaviour.

In Czech

Léčba pacientek s mentální bulimií byla hodnocena prostřednictvím škál EAT, HAMA, CGI a UKU. Fenotypizace probíhala prostřednictvím dextrometorfanového testu. Očekávané zlepšení u bulimických pacientek s pomalou metabolizací se potvrdilo na škále EAT.

Links

MSM0021622404, plan (intention)

Name: Vnitřní organizace a neurobiologické mechanismy funkčních systémů CNS

Investor: Ministry of Education, Youth and Sports of the CR, The internal organisation and neurobiological mechanisms of functional CNS systems under normal and pathological conditions.

Citovat

PALČÍKOVÁ, Ivana, Alexandra ŽOURKOVÁ, Daria VALENTOVÁ and Eva HADAŠOVÁ. Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity. In Addiction and Eating Disorders, Neurobiology nad Comorbidities, Workshop. Brno: Masaryk University Conference Centre, Czech Republic, Brno, 2007, p. 59-60. ISBN 978-80-87041-18-5.

@inproceedings{718302,
   author = {Palčíková, Ivana and Žourková, Alexandra and Valentová, Daria and Hadašová, Eva},
   address = {Brno},
   booktitle = {Addiction and Eating Disorders, Neurobiology nad Comorbidities, Workshop},
   keywords = {bulimia; CYP2D6; paroxetine},
   language = {eng},
   location = {Brno},
   isbn = {978-80-87041-18-5},
   pages = {59-60},
   publisher = {Masaryk University Conference Centre, Czech Republic, Brno},
   title = {Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity},
   year = {2007}
}

TY  - JOUR
ID  - 718302
AU  - Palčíková, Ivana - Žourková, Alexandra - Valentová, Daria - Hadašová, Eva
PY  - 2007
TI  - Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity
PB  - Masaryk University Conference Centre, Czech Republic, Brno
CY  - Brno
SN  - 9788087041185
KW  - bulimia
KW  - CYP2D6
KW  - paroxetine
N2  - P450 enzymes are oxidase systems. These enzymes oxidize endogenous and exogenous compounds and usually render them less active, preparing them for elimination from the body. More than 40 individual P450 enzymes have been identified. 2D6 play important role in drug metabolism. SSRI (serotonin reuptake inhibitors) therapy is used in bulimia. There are SSRI, especially paroxetine, with a SSRI-inhibiting effect. This fact may lead to a change of phenotype. Phenotyping enables to identify the current activity of the enzyme. The study included patients diagnosed with bulimia. The goal of the study was to evaluate the efficacy of paroxetine treatment in female patients with mental bulimia (MB) while monitoring CYP2D6 activity. Treatment was evaluated on EAT, HAMA, CGI and UKU scales. CYP2D6 activity phenotyping was performed using the dextromethorphan test. The expectation of a significant improvement in poor metabolizers and consequently slower paroxetine degradation was confirmed on the scale for eating behaviour.
ER  -

PALČÍKOVÁ, Ivana, Alexandra ŽOURKOVÁ, Daria VALENTOVÁ and Eva HADAŠOVÁ. Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity. In \textit{Addiction and Eating Disorders, Neurobiology nad Comorbidities, Workshop}. Brno: Masaryk University Conference Centre, Czech Republic, Brno, 2007, p.~59-60. ISBN~978-80-87041-18-5.

Detailed Information on Publication Record